The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis

c-MET inhibitors are considered as a kind of novel drugs in non-small cell lung cancer (NSCLC) treatment. However, the results of different clinical studies involving c-MET inhibitors were not consistent. In this report, we performed Meta-analysis to investigate the beneficial and harmful effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Sa, Li, Jiuke, Hao, Ke, Yan, Jianping, Zhou, Hongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081544/
https://www.ncbi.nlm.nih.gov/pubmed/27786238
http://dx.doi.org/10.1038/srep35770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081544/
https://www.ncbi.nlm.nih.gov/pubmed/27786238
http://dx.doi.org/10.1038/srep35770

Ejemplares similares